General
Preferred name
DOXORUBICIN
Synonyms
DOXORUBICIN HYDROCHLORIDE ()
Doxil,Rubex ()
Adriamycin ()
NSC 123127 ()
Hydroxydaunorubicin hydrochloride ()
Adriamycin HCl ()
DOX hydrochloride ()
Doxorubicin (HCl) ()
Doxorubicin HCl ()
Doxorubicin (hydrochloride) ()
Hydroxydaunorubicin (hydrochloride) ()
ADR ()
NSC 123127, DOX, Doxorubicin hydrochloride, Hydroxydaunorubicin HCl,Adriamycin HCl ()
Adriamycin,Hydroxydaunorubicin ()
Doxorubicin (Adriamycin) HCl ()
Doxorubicina ()
NSC-123127 ()
Doxorubicine ()
Hydroxydaunorubicin ()
Adriblastina ()
Valrubicin impurity, doxorubicin ()
NSC-759155 ()
Adriablastin ()
Epirubicin hydrochloride impurity, doxorubicin- ()
Doxorubicin HCl ()
Adriablastina cs ()
Myocet liposomal (previously myocet) ()
Doxorubicin hydrochloride (liposomal) ()
Doxorubicin citrate ()
Caelyx pegylated liposomal ()
Doxil (liposomal) ()
Liposomal doxorubicin hydrochloride ()
Celdoxome pegylated liposomal ()
Adriamycin Pfs ()
Adriamycin, hydrochloride ()
Caelyx ()
Zolsketil pegylated liposomal ()
Rubex ()
Doxorubicin hydrochloride component of imx-110 ()
Myocet ()
Doxil ()
Doxorubicin liposomal complex of the hydrochloride ()
Doxorubicini hydrochloridum ()
Adriamycin Rdf ()
Hydroxydaunomycin hydrochloride ()
Doxorubicin citric acid salt ()
P&D ID
PD003620
CAS
25316-40-9
111266-55-8
23214-92-8
Tags
available
drug
natural product
nuisance
obsolete probe
Approved by
EMA
PMDA
FDA
First approval
1974
Drug indication
Breast cancer
ovarian neoplasm
Tumour
Hepatocellular carcinoma
Solid tumour/cancer
breast carcinoma
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Doxorubicin is an anthracycline type anti-neoplastic drug. (GtoPdb)
PRICE 29
DESCRIPTION Doxorubicin (Adriamycin) is a Topoisomerase II (Top2) inhibitor with antineoplastic activity.
DESCRIPTION Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 ¦ÌM and 2.67 ¦ÌM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].
PRICE 29
DESCRIPTION Doxorubicin hydrochloride (Adriamycin) belongs to the anthracycline class of antibiotics and is an inhibitor of human DNA topoisomerase I/II (IC50=0.8/2.67 ??M). Doxorubicin hydrochloride exhibits cytotoxicity and antitumor activity. Doxorubicin hydrochloride reduces the phosphorylation of AMPK and its downstream target protein acetyl coenzyme A carboxylase, and induces apoptosis and autophagy.
DESCRIPTION inhibitor of topoisomerase II (Informer Set)
DESCRIPTION Inhibits NGF binding to p75NTR and TrkA (Tocris Bioactive Compound Library)
DESCRIPTION Antitumor antibiotic agent. Inhibits DNA topoisomerase II (Tocriscreen Plus)
DESCRIPTION Antitumor antibiotic agent. Inhibits DNA topoisomerase II (Tocriscreen Total)
DESCRIPTION Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. It is used to treat various cancers and Kaposi's Sarcoma. (Enamine Bioactive Compounds)
DESCRIPTION Doxorubicin hydrochloride (Adriamycin) belongs to the anthracycline class of antibiotics and is an inhibitor of human DNA topoisomerase I/II (IC50=0.8/2.67 μM). Doxorubicin hydrochloride exhibits cytotoxicity and antitumor activity. Doxorubicin hydrochloride reduces the phosphorylation of AMPK and its downstream target protein acetyl coenzyme A carboxylase, and induces apoptosis and autophagy. (TargetMol Bioactive Compound Library)
Cell lines
868
Organisms
10
Compound Sets
37
AdooQ Bioactive Compound Library
A10041
Cayman Chemical Bioactives
15007
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL53463
CHEMBL359744
ChEMBL Drugs
CHEMBL53463
CHEMBL359744
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00997
DrugBank Approved Drugs
DB00997
DrugCentral
960
DrugCentral Approved Drugs
960
DrugMAP
DMVP5YE
DrugMAP Approved Drugs
DMVP5YE
Enamine Bioactive Compounds
EBC-11150
Enamine BioReference Compounds
Guide to Pharmacology
7069
Informer Set
36599
LINCS compound set
10248-101
10248-102
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL53463
CHEMBL359744
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL53463
MedChem Express Bioactive Compound Library
HY-15142
NCATS Inxight Approved Drugs
80168379AG
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Obsolete Compounds
doxorubicin
Prestwick Chemical Library
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
Selleckchem Bioactive Compound Library
doxorubicin
Adriamycin
TargetMol Bioactive Compound Library
T1020
Tocris Bioactive Compound Library
2252
Tocriscreen Plus
2252
Tocriscreen Total
Welcome Trust Cancer Drugs
133
ZINC Tool Compounds
ZINC000003918087
External IDs
89
Properties
(calculated by RDKit )
Molecular Weight
543.17
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
6
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
2
cLogP
0.0
TPSA
206.07
Fraction CSP3
0.44
Chiral centers
6.0
Largest ring
6.0
QED
0.24
Structural alerts
6
quinone_A(370)
[!#6&!#1]=[#6]1[#6]=,:[#6][#6](=[!#6&!#1])[#6]=,:[#6]1
PAINS Family A
aggregator (Aggregator Advisor)
Aggregators
historic compounds (Chemical Probes.org)
Obsolete
aggregator (ZINC)
Aggregators
Intercalation
Nuisance compounds
Optical interference
Fluorescence
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
TOP2A
DNA intercalating
ADC Cytotoxin
Autophagy
AMPK
Mitophagy
DNA topoisomerase II alpha
DNA
HCV
HBV
HIV
ADC Payload
antibiotic
Bacterial
ADC Cytotoxin,AMPK,Antibiotics,Antineoplastic and Immunosuppressive Antibiotics,Apoptosis related,HIV,Mitophagy,Topoisomerase
Topo II
Compound status
FDA
Pathway
DNA replication
Cell Cycle/DNA Damage
Antibody-drug Conjugate/ADC Related
Epigenetics
PI3K/Akt/mTOR
Apoptosis
Chromatin/Epigenetic
DNA Damage/DNA Repair
Microbiology/virology
PI3K/Akt/mTOR signaling
Proteases/Proteasome
Anti-infection
Target Type
Enzymes
MOA
DNA intercalator
Topoisomerase inhibitor
Topoisomerase
Inhibitor
Topoisomerase II modulator
Primary Target
DNA Topoisomerases
Member status
member
Indication
acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma
Disease Area
hematologic malignancy, oncology
Cellular injury category
Genotoxin
Therapeutic Class
Anticancer Agents
Source data